nadunolimab
cantargia
['nadunolimab', 'pancreatic', 'cantargia']
cantargia presents new clinical data at aacr 2023 strongly supporting nadunolimab development in pancreatic cancer 
Småsparare på börsen sen 2015 Cantargia ägare sedan 2016